FDA’s Drug Safety Office Is Already Independent, CDER Director Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting CDER Director Galson responds to calls for greater independence of drug safety functions by noting that both the Office of Drug Safety and Office of New Drugs report directly to him. FDA will “continue its longstanding practice of assessing the safety of all drugs” using “sound science,” Galson says.
You may also be interested in...
FDA's Crawford Open To Discussing Independent Drug Safety Office
Acting Commissioner Crawford tells members of the Senate Health Committee during his confirmation hearing that he is willing to talk about a more independent safety review office. However, the commissioner nominee also says the Office of Drug Safety already is "operating independently."
FDA's Crawford Open To Discussing Independent Drug Safety Office
Acting Commissioner Crawford tells members of the Senate Health Committee during his confirmation hearing that he is willing to talk about a more independent safety review office. However, the commissioner nominee also says the Office of Drug Safety already is "operating independently."
FDA Authority To Require Rx Label Changes Would Be "Helpful," Kweder Says
Officer of New Drugs Deputy Director Kweder tells Senate Health Committee that the agency lacks the ability to dictate the contents of drug labeling, but that the power to do so "would be very helpful." Kweder notes it took over a year to negotiate the addition of cardiovascular risk information to Merck's Vioxx.